Oxytocin acetate - CAS 6233-83-6
Catalog number: 6233-83-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Oxytocin acetate is a mammalian neurohypophysial hormone. Its actions are mediated by specific, high-affinity oxytocin receptors. Oxytocin is normally produced in the hypothalamus and stored in the posterior pituitary gland, which plays a role in intimacy, sexual reproduction of both sexes, and during and after childbirth.
Related CAS:
50-56-6 (Free base)
Solid powder
(S)-N-((S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-((S)-sec-butyl)-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide acetate; Orasthin; Ossitocina; Ossitocina; Oxetakain; Oxitocina; Oxoject; Oxystin; Partocon; Pitocin; Piton S; Oxt,; Oxytocin
Canonical SMILES:
1.Large Scale Solid Phase Synthesis of Peptide Drugs: Use of Commercial Anion Exchange Resin as Quenching Agent for Removal of Iodine during Disulphide Bond Formation.
Reddy KM1, Kumari YB, Mallikharjunasarma D, Bulliraju K, Sreelatha V, Ananda K. Int J Pept. 2012;2012:323907. doi: 10.1155/2012/323907. Epub 2012 Oct 15.
The S-acetamidomethyl (Acm) or trityl (Trt) protecting groups are widely used in the chemical synthesis of peptides that contain one or more disulfide bonds. Treatment of peptides containing S-Acm protecting group with iodine results in simultaneous removal of the sulfhydryl protecting group and disulfide formation. However, the excess iodine needs to be quenched or adsorbed as quickly as possible after completion of the disulfide bond formation in order to minimize side reactions that are often associated with the iodination step. We report here a simple method for simultaneous quenching and removal of iodine and isolation of disulphide bridge peptides. The use of excess inexpensive anion exchange resin to the oxidized peptide from the aqueous acetic acid/methanol solution affords quantitative removal of iodine and other color impurities. This improves the resin life time of expensive chromatography media that is used in preparative HPLC column during the purification of peptide using preparative HPLC.
2.Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations.
Poole RA1, Kasper PT, Jiskoot W. J Pharm Sci. 2011 Jul;100(7):3018-22. doi: 10.1002/jps.22495. Epub 2011 Jan 25.
Citric acid is widely used to buffer pharmaceutical formulations including protein pharmaceuticals. In accelerated stability studies of the small cyclic peptide oxytocin, we have noted that additional degradation products form when oxytocin is formulated in citrate that do not form in other common buffers such as acetate and phosphate. Using high-pressure liquid chromatography combined with high-resolution and tandem mass spectrometry, we identified these degradation products as amide- and imide-linked adducts of oxytocin and citrate. The site of reaction was shown to be the N-terminal amine of cysteine. The adducts have been found to form for oxytocin formulated in citrate buffer over the pH range of 3-6; the extent of formation is greatest at a pH of 4-4.5. We have additionally identified these same adducts in samples of oxytocin formulated in citrate buffer that had been stored in the dark for 3 months at room temperature. Altogether, these results demonstrate that reaction between citrate and oxytocin leads to the formation of covalent amide- and imide-linked adducts.
3.The effect of combination treatment with trenbolone acetate and estradiol-17β on skeletal muscle expression and plasma concentrations of oxytocin in sheep.
Kongsuwan K1, Knox MR, Allingham PG, Pearson R, Dalrymple BP. Domest Anim Endocrinol. 2012 Jul;43(1):67-73. doi: 10.1016/j.domaniend.2012.02.004. Epub 2012 Mar 20.
Implantation of trenbolone acetate (TBA) in conjunction with estradiol-17β (E(2)) increases growth, feed conversion efficiency, and carcass leanness in cattle. Our previous study in Brahman steers suggested that the neuropeptide hormone oxytocin (OXT) may be involved in increasing muscle growth after TBA-E(2) treatment. The present study aimed to determine whether OXT mRNA expression in the longissimus muscle (LM) is also up-regulated in TBA-E(2-)implanted wethers as has been found in steers. Real-time quantitative PCR was used to measure the expression of the gene encoding the OXT precursor, three genes with increased expression in the LM muscle of TBA-E(2)-treated steers, MYOD1 (muscle transcription factor), GREB1 (growth regulation by estrogen in breast cancer 1), and WISP2 (Wnt-1 inducible signaling pathway protein 2), and two genes encoding IGF pathway proteins, IGF1, IGFR, in the LM of both untreated and TBA-E(2)-treated wethers. The expression of OXT mRNA in wethers that received the TBA-E(2) treatment was increased ~4.
4.Short-lived corpora lutea syndrome in anoestrous ewes following 17β-oestradiol or MAP treatments applied before an allogenic sexual stimulation with rams and oestrous ewes.
Rodríguez Iglesias RM1, Ciccioli NH, Ferrería J, Pevsner DA, Rosas CA, Rodríguez MM, Pedrueza JR. Anim Reprod Sci. 2013 Jan 30;136(4):268-79. doi: 10.1016/j.anireprosci.2012.11.009. Epub 2012 Nov 27.
When induced to ovulate during anoestrus, ewes, does and cows frequently develop a short-lived corpora lutea (SLCL) syndrome associated to lack of previous progesterone. Exogenous progesterone precludes SLCL by blocking oxytocin endometrial receptors, thus inducing normal life-span CL (NLCL). Paradoxically, circa 50% of unprimed ewes do not develop SLCL. We report results from 3 trials assessing follicular, oestrous, ovulatory, and luteal end-points after 17β-oestradiol or MAP treatments. Oestradiol benzoate (50μg) induced follicular turnover, provoked ovulation in 40% (24/60) of ewes treated (93% of which developed SLCL), but did not affect the incidence of SLCL (26/53) after an allogenic sexual stimulation (ASS) by rams and oestrous ewes. By the onset of the ASS, most NLCL ewes (26/27) had already experienced turnover of their largest follicle, had smaller largest and second largest follicles, and ovulated their largest follicle more frequently than SLCL ewes did.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

(CAS: 1303469-70-6)

KHK-IN-1, a pyrimidinopyrimidine derivative, is a ketohexokinase inhibitor that could have probable effect against diabetes and obesity by acting on Asp-27B in ...

CAS 42924-53-8 Nabumetone

(CAS: 42924-53-8)

Nabumetone is a non-steroidal anti-inflammatory drug and its active metabolite inhibits the COX.

CAS 93479-97-1 Glimepiride

(CAS: 93479-97-1)

Glimepiride is a medium- to long-acting sulfonylurea antidiabetic drug.

CAS 98753-19-6 Cefpirome Sulfate

Cefpirome Sulfate
(CAS: 98753-19-6)

Cefpirome Sulfate is a fourth generation cephalosporin antibiotic. It was developed by German company Hoechst and France Roussel company together.

CAS 6537-80-0 Chicoric acid

Chicoric acid
(CAS: 6537-80-0)

Chicoric Acid, a natural product, is reported to be antioxidative, is an effective inhibitor of human immunodeficiency virus type-1 (HIV-1) integrase and the re...

CAS 1357349-91-7 SPP 86

SPP 86
(CAS: 1357349-91-7)

SPP 86 is a potent and cell-permeable RET inhibitor (IC50 = 8 nM). It also inhibits EphA1, FGFR1, Flt4, Lck and Yes. SPP 86 suppresses the proliferation of HCT ...

(CAS: 1414375-50-0)

GSK-1268997 is one of a metabolite of Pazopanib which is a selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits an...

MDL-72274 HCl
(CAS: 85278-24-6)

MDL-72274 is a selective SSAO inhibitor. It is a potent (IC50 = 10(-9) M) inhibitor of both MAO-B and SSAO, with 190-fold lower affinity for MAO-A. MDL-72974 ca...

Chemical Structure

CAS 6233-83-6 Oxytocin acetate

Quick Inquiry

Verification code

Featured Items